Your session is about to expire
← Back to Search
Procedure
PA-LAA shunt for Left Atrial Appendage Thrombus Prevention (PA-LAA Trial)
N/A
Waitlist Available
Led By Benjamin Hibbert, MD PhD
Research Sponsored by Ottawa Heart Institute Research Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
PA-LAA Trial Summary
This trial will test a new, minimally invasive procedure to treat atrial fibrillation and reduce the risk of stroke.
Eligible Conditions
- Left Atrial Appendage Thrombus Prevention
PA-LAA Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Composite of device safety and performance
Secondary outcome measures
Device related performance - maintaining patency
Need for intervention to close the shunt
Systemic embolization
+1 morePA-LAA Trial Design
1Treatment groups
Experimental Treatment
Group I: Procedure armExperimental Treatment1 Intervention
At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
Find a Location
Who is running the clinical trial?
Ottawa Heart Institute Research CorporationLead Sponsor
188 Previous Clinical Trials
92,436 Total Patients Enrolled
Benjamin Hibbert, MD PhDPrincipal InvestigatorOttawa Heart Institute Research Corporation
2 Previous Clinical Trials
236 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger